CNS Stimulant Drugs Market Players:
- Shire Pharmaceuticals LLC
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Novartis International AG
- Johnson & Johnson
- Eli Lilly and Company
- Pfizer Inc.
- GlaxoSmithKline plc
- Teva Pharmaceutical Industries Ltd.
- AbbVie Inc.
- Purdue Pharma L.P.
- Mallinckrodt Pharmaceuticals
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of CNS stimulant drugs is assessed at USD 9.87 billion.
The global CNS stimulant drugs market size surpassed USD 9.4 billion in 2025 and is projected to witness a CAGR of more than 5.5%, crossing USD 16.06 billion revenue by 2035.
Asia Pacific central nervous system (CNS) stimulant drugs market achieves a 38% share by 2035, attributed to technological developments in healthcare infrastructure and improved access to advanced diagnostic tools.
Key players in the market include Shire Pharmaceuticals LLC, Novartis International AG, Johnson & Johnson, Eli Lilly and Company, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Purdue Pharma L.P., Mallinckrodt Pharmaceuticals.
